Angiogenesis Markers in Primiparas Versus Multiparas: Relevance to Preeclampsia Incidence
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00262093|
Recruitment Status : Unknown
Verified November 2005 by Hadassah Medical Organization.
Recruitment status was: Recruiting
First Posted : December 6, 2005
Last Update Posted : March 20, 2007
|Condition or disease|
Primiparity is one of the main risk factors for having preeclampsia during pregnancy. Recently, sFlt-1, soluble FMS-like tyrosine kinase-1, has been shown to be a major molecule involved in the pathogenesis of preeclampsia. Higher sFlt-1 mRNA, higher serum levels of sFlt-1 as well as lower PlGF, placental growth factor, have been found in preeclamptic patients.
We intend to check the angiogenesis profile of primiparas as compared to multiparas.
|Study Type :||Observational|
|Estimated Enrollment :||200 participants|
|Observational Model:||Case Control|
|Official Title:||Angiogenesis Markers in Primiparas Versus Multiparas: Relevance to Preeclampsia Incidence|
|Study Start Date :||November 2005|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00262093
|Contact: Yuval Bdolah, MD, MScfirstname.lastname@example.org|
|Contact: Hadas Lemberg, PhDemail@example.com|
|Hadassah Medical Organization||Recruiting|
|Jerusalem, Israel, 91240|
|Contact: Arik Tzukert, DMD 972 2 6776095 firstname.lastname@example.org|
|Contact: Hadas Lemberg, PhD 972 2 6777572 email@example.com|
|Principal Investigator: Yuval Bdolah, MD|
|Principal Investigator:||Yuval Bdolah, MD, MSc||Hadassah-Hebrew University Medical School|